Masimo Corp - MASI STOCK NEWS

Masimo (NASDAQ: MASI) reported findings from a study presented at the Society for Technology in Anesthesia 2022 Annual Meeting. The study analyzed pulse oximetry data and found no significant bias based on ethnicity among black and white subjects monitored with Masimo's SET® pulse oximetry technology. The analysis included 7,183 paired samples and revealed that the bias difference was 0.15%, which is not clinically significant. Masimo plans to conduct additional studies to further explore these findings.

Masimo Corporation (NASDAQ: MASI) has announced preliminary financial results for the full year 2021 and guidance for 2022. For 2021, product revenues are projected between $1,235 million and $1,240 million, representing an increase of approximately 8.0% to 8.4%. The company expects GAAP and non-GAAP earnings per diluted share to exceed earlier guidance of $3.88. Looking ahead, Masimo forecasts product revenue of approximately $1,350 million and GAAP earnings per diluted share of $4.27 for 2022. The fourth quarter results will be discussed on February 15, 2022.

Masimo (NASDAQ: MASI) revealed findings from a prospective study published in Anesthesia & Analgesia highlighting a correlation between EEG-based markers and postoperative delirium (POD) in older elective surgery patients. Out of 237 patients, 17% developed POD, with lower preoperative spectral edge frequency (SEF) and gamma-band power linked to increased risk. The study suggests EEG markers could assist in identifying at-risk patients, emphasizing the importance of brain function monitoring for improving outcomes in geriatric surgery.

Masimo (NASDAQ: MASI) announced the results of a study published in Clinical Medicine Insights: Pediatrics, showing the effectiveness of its Rad-G® Pulse Oximeter in detecting pneumonia in over 4,500 children under five in India. The study indicated that Rad-G helped achieve over 91% accurate case management of acute respiratory infections, reducing unnecessary antibiotic use. Researchers noted that Rad-G's usability and reliability make it suitable for low-resource settings, potentially transforming pneumonia diagnosis. The study highlights the critical need for improved pneumonia management tools in India, where pneumonia contributes to significant child mortality.

MDoloris Medical Systems has received regulatory clearance and marketing approval for its HFVI MOC-9 monitor in Japan. This innovation is the first of its kind for monitoring patients under analgosedation and anesthesia in Japan, integrating with Masimo's Root patient monitoring hub. The HFVI MOC-9 improves assessment of parasympathetic activity during surgeries, enhancing postoperative outcomes and reducing opioid use. Heiwa Bussan will exclusively market this technology in Japan, indicating strong sales potential in a significant market.

Masimo (NASDAQ: MASI) is set to participate in the Piper Sandler 33rd Annual Healthcare Conference on November 30, 2021, at 2:00 p.m. Eastern Time. The event will feature a live webcast available on the Masimo website, with a replay option for later viewing. Masimo is recognized for its advanced medical monitoring technologies and aims to enhance patient care while reducing associated costs. Its pulse oximetry technology is utilized in top hospitals globally, proving a significant impact on patient outcomes.

Masimo (NASDAQ: MASI) released findings from a study published in Frontiers in Neurology demonstrating that its SedLine^® Brain Function Monitoring can significantly reduce the incidence of postoperative delirium (POD) in carotid endarterectomy patients. In a trial with 255 participants, those monitored with SedLine exhibited a 7.87% POD rate compared to 28.91% for standard monitoring (p < 0.01). The study highlights the potential for improved patient outcomes through enhanced anesthesia management using multiple EEG parameters.

Masimo (NASDAQ: MASI) will participate in the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 4:00 p.m. Eastern Time. A live webcast can be accessed via the Masimo website, with a replay available post-event. Masimo is known for its innovative medical technologies including pulse oximetry that enhances patient monitoring. Established in 1995, their SET® technology is used globally, improving outcomes and reducing healthcare costs. For more details, visit www.masimo.com.

Masimo (NASDAQ: MASI) announced a study published in Frontiers in Aging Neuroscience indicating that its Root® monitoring platform could enhance postoperative cognitive function in elderly patients undergoing spinal surgery. The study involved 26 patients, showing that the intervention group managed with a multimodal algorithm had a higher mean postoperative MoCA score (24.80) compared to the control group (22.56). The research suggests that the algorithm's precision in monitoring could reduce the risk of postoperative neurocognitive disorder.